Literature DB >> 26226170

Serial Ultrasound Findings After Laser Ablation for Benign Breast Lesions on Long-Term Follow-Up: Implications for Evaluation of Procedural Success.

Bo Ra Yang1, Hye Jung Kim2, Kyung Min Shin2, Seung Hyeon Cho2, Yun-Jin Jang1, Hui Joong Lee1, Young Mi Park3, So Mi Lee2, Ji Young Park4, Ho Yong Park5, Jin Hyang Jung5.   

Abstract

OBJECTIVE: The purpose if this study was to describe the follow-up ultrasound (US) findings of percutaneous US-guided laser ablation for small benign breast lesions, and to define the procedural success. BACKGROUND DATA: There are limited reports on follow-up imaging after laser ablation, because the ablated tumors were generally resected by surgery.
MATERIALS AND METHODS: US-guided laser ablation was performed on 19 benign breast lesions in 10 patients. The median size of the lesions was 7.8 mm (range, 3-11 mm). The lesions were diagnosed as image-pathology concordant benign by US-guided core biopsy. After ablation, we performed follow-up US with an interval of 3-12 months; the median follow-up period was 32 months (range, 30-36 months). We evaluated the morphologic and size changes by using serial follow-up US.
RESULTS: US findings of the 13 cases followed within the first 6 months after ablation showed hypoechoic lesions having inner hyperechogenicity with or without a hypoechoic center. The size of these lesions during this period increased in comparison with the initial lesion size, and then decreased or became stable on serial follow-up US. On the last follow-up US examination, in 14 cases (73.6%), the lesions were invisible, 4 cases (21.1%) showed scar changes, and 1 case (5.3%) showed a hypoechoic remnant lesion.
CONCLUSIONS: US findings within 6 months after laser ablation showed mixed echoic lesions with increased size, followed by gradual decrease in size. Therefore, the success of laser ablation may be evaluated by checking the changes in the lesions by comparing the size of the lesions with the first follow-up US within 6 months and not the original tumor.

Entities:  

Mesh:

Year:  2015        PMID: 26226170     DOI: 10.1089/pho.2015.3932

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  2 in total

1.  Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial.

Authors:  Sadaf Alipour; Mahboubeh Abedi; Azin Saberi; Arezoo Maleki-Hajiagha; Firoozeh Faiz; Saeed Shahsavari; Bita Eslami
Journal:  BMC Endocr Disord       Date:  2021-08-20       Impact factor: 2.763

2.  Ultrasound guided percutaneous microwave ablation of benign breast lesions.

Authors:  Jie Yu; Bao-Hua Chen; Jing Zhang; Zhi-Yu Han; Han Wu; Yan Huang; Meng-Juan Mu; Ping Liang
Journal:  Oncotarget       Date:  2017-05-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.